Theriva Biologics (NYSE: TOVX) cuts 32% of staff to cut costs

Rhea-AI Filing Summary

Theriva Biologics, Inc. approved a restructuring plan on September 28, 2025 to resize the company and focus resources on business development, licensing, and upcoming regulatory meetings for its lead oncolytic virus candidate VCN-01 in metastatic pancreatic ductal adenocarcinoma and retinoblastoma.

As part of the plan, Theriva implemented a workforce reduction on September 30, 2025, eliminating approximately seven positions, or about 32% of its global workforce. The company expects to record about $520,000 of charges in the fourth quarter of 2025, primarily for cash severance and benefits over roughly three months.

The restructuring is expected to reduce annual compensation and benefits costs by about $2.0 million. Together with additional anticipated operating cost reductions, Theriva believes this will extend its cash runway into the second quarter of 2026, though it cautions that actual charges and savings may differ materially due to legal and operational factors.

Positive

• None.

Negative

• Theriva initiates major workforce reduction, cutting about 32% of its global employees and recording roughly $520,000 in severance and benefit charges to reduce costs and extend its cash runway.

Insights

Biotech equity analyst

Theriva cuts 32% of staff to lower costs and fund VCN-01 focus.

Theriva Biologics is executing a significant restructuring to concentrate on business development, licensing, and advancing VCN-01 in pancreatic ductal adenocarcinoma and retinoblastoma. The plan includes a workforce reduction of about seven employees, representing roughly 32% of its global workforce, signaling a leaner operating model.

The company expects about $520,000 in severance and benefit charges in Q4 2025, in exchange for an anticipated $2.0 million annual reduction in compensation and benefits. Management states that, along with other cost cuts, this should extend the cash runway into the second quarter of 2026, which is important for funding planned clinical and regulatory activities around VCN-01.

The move underscores a tradeoff: lower ongoing expenses and a sharper focus on the lead asset, offset by organizational disruption and execution risk around clinical trial progress and partnering. Future company reports will show whether the projected savings and cash runway extension materialize as described.

8-K Event Classification

2 items: 2.05, 9.01

2 items

Item 2.05 Costs Associated with Exit or Disposal Activities Financial

The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

FAQ

What restructuring did Theriva Biologics (TOVX) approve in September 2025?

On September 28, 2025, Theriva Biologics approved a plan to resize and restructure the company so it can focus on business development, licensing, and upcoming regulatory meetings and clinical trial plans for its lead candidate VCN-01 in pancreatic ductal adenocarcinoma and retinoblastoma.

How many employees is Theriva Biologics (TOVX) laying off and what percentage of its workforce is that?

Under the plan, Theriva implemented a workforce reduction on September 30, 2025 affecting approximately seven employees, which represents about 32% of its current global workforce.

What charges will Theriva Biologics (TOVX) record from the workforce reduction?

Theriva estimates it will incur total charges of approximately $520,000 in connection with the workforce reduction, primarily cash severance and benefits over a three-month period, all expected to be recorded in the fourth quarter of 2025.

How much does Theriva Biologics (TOVX) expect to save annually from this restructuring?

The plan is expected to save approximately $2.0 million per year in compensation and benefits, and together with other anticipated operating cost reductions, the company believes this will help extend its cash runway into the second quarter of 2026.

Which drug candidate is central to Theriva Biologics’ (TOVX) new focus?

The restructuring is centered on advancing VCN-01, a clinical-stage oncolytic human adenovirus modified for tumor-selective replication and expression of the enzyme PH20 (hyaluronidase), which has been evaluated in a Phase 2b study in pancreatic cancer (VIRAGE) and a Phase 1 study in retinoblastoma.

What risks did Theriva Biologics (TOVX) highlight regarding its restructuring plan and cost estimates?

Theriva noted that its cost and timing estimates for the workforce reduction are subject to assumptions, including local law requirements in various jurisdictions, and that actual amounts may differ materially; it also cautioned that additional unanticipated charges or cash expenditures could arise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/02/2025 - 04:01 PM Learn about SEC filing dates

false 0000894158 0000894158 2025-09-28 2025-09-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2025

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-12584		13-3808303
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

(301) 417-4364

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	TOVX	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.05 Costs Associated with Exit or Disposal Activities.

On September 28, 2025, the Board of Directors of Theriva Biologics, Inc. (the “Company”) approved a plan to resize and restructure the Company (the “Plan”) for purposes of focusing its attention on business development and licensing activities and the Company’s upcoming meetings with the U.S. Food and Drug Administration and the European Medicines Agency for planned clinical trials in patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) and retinoblastoma. The Company’s lead product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express an enzyme, PH20 or hyaluronidase, has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer (“VIRAGE”), and has recently been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma.

Pursuant to the Plan, on September 30, 2025, the Company implemented a workforce reduction of approximately seven employees or 32% of the current global Company workforce. The goal of this reduction is to direct the Company’s resources towards business development and licensing activities and clinical trial plans and preparation for VCN-01 in patients with PDAC and retinoblastoma, which it believes will represent its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and benefits over a three-month period, in connection with the workforce reduction. The Plan is expected to save approximately $2.0 million in compensation and benefits annually, and together with additional anticipated operating cost reductions the Company expects that it will extend its cash runway into the second quarter of 2026.

The estimates of the charges and expenditures that the Company expects to incur in connection with the workforce reduction, and the timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ materially from estimates. The Company may also incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur.

This Item 2.05 contains “forward-looking” statements and estimates, including anticipated cost reductions and estimated resizing, refocusing and restructuring costs. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the Company will successfully advance its clinical trials of VCN-01, whether anticipated annual cost reductions will be achieved and other risks detailed in the “Risk Factors” section of the Company’s most recent periodic report filed with the Securities and Exchange Commission. These statements represent the Company’s estimates and assumptions only as of the date of this Current Report on Form 8-K. The Company does not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 2, 2025	THERIVA BIOLOGICS, INC.
	By:	/s/ Steven A. Shallcross
		Name:	Steven A. Shallcross
		Title:	Chief Executive Officer and Chief Financial Officer